Introducing QVCAD ABUS from QView Medical
Pioneers for over 50 years in Breast Cancer Detection
QVCAD has been developed over six years by a group of AI experts with over 100 years of combined experience. It has been used in over 20,000 ABUS cases, 3000 of which are only ABUS cancer cases. In comparison, less than 500 cancers will be seen in a lifetime of a typical breast radiologist. Approximately 30 sites around the world, including those of many key opinion leaders, have used QVCAD.
Bob Wang is Chief Executive Officer and Chairman. He is an executive with great vision and proven accomplishment in establishing companies that have changed medical imaging and breast care over the past 30 years. When he first started in medical imaging, mammography was deemed unsafe for screening purposes due to its high radiation exposure levels. The high-resolution and low-dose rare-earth x-ray radiography technology developed by Bob, which was sold to 3M with a license to Kodak, allowed a 95% dose reduction to mammography and gave rise to modern mammography screening as we know it today. This rare-earth technology was adopted worldwide for all x-ray radiographic procedures, a multi-billion dollar business, due mainly to its ability to reduce x-ray dosage. Bob went on to start R2 Technology, introducing the world’s first and still most widely used Computer Aided Diagnosis (CAD) system to mammography. R2 was acquired by Hologic in 2006. Bob also observed that mammography did not detect a significant proportion of earlier cancers, especially in women with dense breast tissue, and that ultrasound was more effective in doing so. Bob founded U-Systems and developed the technology behind the somo.v, an automated breast ultrasound system that became the first FDA-cleared ultrasound breast screening device. U-Systems was acquired by GE Healthcare in 2012. Bob holds degrees from MIT and Rensselaer Polytechnic Institute.
Ron Ho is a member of the Board of Directors. He was most recently the Chief Executive Officer of U-Systems, a medical device start-up company developing an automated ultrasound breast cancer screening system, leading the company to a successful exit with GE Healthcare in November 2012. Prior to Joining U-Systems, Mr. Ho led Metron Systems, an advanced laser scanning company providing precise 3D digitization of complex parts for the medical and aerospace industries. Prior to Metron, Mr. Ho spent 16 years with Siemens Medical Solutions' Ultrasound Group in various positions including executive senior management of R&D and operations. He was responsible for product development and production for all of Siemens ultrasonic transducers as well as for initiating and growing a joint venture company, Ultrasonic Technologies Limited (UTL) in Gyongju, Korea, currently the world’s largest dedicated ultrasound transducer operation. Mr. Ho currently serves on the board of various medical device companies and holds BSME and MSME degrees from the University of Washington. He has been granted several ultrasound-related patents.
Wei Zhang is Vice President of Engineering. He has extensive experience in image processing and Computer Aided Diagnosis (CAD) algorithm development. He has been a founding member and held management positions in various startup companies. Prior to QView, he was Vice President of Advanced Development at O2 MedTech, responsible for Algorithm development. Prior to O2, he was Vice President of Advanced Software Development at U-Systems responsible for developing the viewing workstation and 3D ultrasound image processing. Prior to U-Systems, he was Director of CAD Algorithm at R2 Technology, responsible for CAD algorithm development of both breast cancer and lung cancer product families. Prior to R2, he was an Assistant Professor at the Department of Radiology at the University of Chicago. Wei Zhang has a Ph.D. in Applied Physics from the University of Osaka, Japan.
Bob Foley is Vice President of Regulatory Affairs and Marketing Strategy. He has more than twenty-five years of experience in medical imaging. Prior to Qview, Bob was principal at R2 Healthcare Consulting, advising start-up medical imaging companies on accelerated regulatory pathways to the marketplace. From 2004 to 2010, he held various executive positions with U-Systems, responsible for fundraising, structuring clinical studies and reimbursement strategies. Prior to that, Bob held several executive positions most notably at R2 Technology, the first FDA approved systems for Computer Aided Detection (CAD) for breast and lung cancer, and Integrated Surgical Systems (Robodoc), the first and only active robot that has performed human surgery. Bob holds a BS from College of the Holy Cross and MS from Iowa State University.
Nico Karssemeijer, Senior Consultant to QView Medical, is Professor of Computer Aided Diagnosis (CAD). He heads the Diagnostic Image Analysis Group (DIAG) in the Department of Radiology of the Radboud University Nijmegen Medical Center, while his professorship is in the Intelligent Systems of the Institute for Computing and Information Sciences (iCIS). He is Associate Editor of IEEE Transactions on Medical Imaging, and member of the Editorial Boards of Physics in Medicine and Biology and Medical Image Analysis. In 2012 and 2013 he was symposium chair of SPIE Medical Imaging, one of the major scientific conferences in the field of Medical Imaging. Nico Karssemeijer was closely involved at R2 Technology in developing the R2 ImageChecker, the most widely used CAD system to date. He is co-founder at Matakina, Ltd. (Wellington, New Zealand), a company that develops technology for quantitative mammography. He studied Physics at Delft University of Technology and graduated from the Radboud University Nijmegen.
Join Our Team
Please send your resume to